Tumoricidal interactions of hyperthermia with carboplatin, cisplatin and etoposide

• Published in: Cancer letters Vol. 44; no. 3; pp. 205 - 210
• Main Authors: Cohen, J.D., Robins, H.I., Schmitt, C.L.
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 01.03.1989; Elsevier
• Subjects: Antineoplastic Agents - pharmacology; Biological and medical sciences; Carboplatin; Cell Survival - drug effects; Cisplatin - pharmacology; Combined Modality Therapy; Combined treatment; cytotoxicity; Drug Synergism; Etoposide - pharmacology; Hot Temperature; hyperthermia; Medical sciences; Organoplatinum Compounds - pharmacology; Treatment. General aspects; Tumor Cells, Cultured - drug effects; Tumors; hyperthermia; carboplatin; cytotoxicity; Antineoplastic agent; Human; Potentiation; Cytotoxicity; Experimental study; Chemotherapy; Cell line; Combined treatment; Acute lymphocytic leukemia; T»-Lymphocyte; Survival curve; Comparative study; Induced hyperthermia; Platinum II Complexes
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/0304-3835(89)90062-1

Interactions of hyperthermia with carboplatin, cisplatin and etoposide were investigated in vitro in JM, a human, T cell, lymphoblastic cell line. Thermal enhancement ratios (TER) for carboplatin killing increased with temperature (2.3 at 40.5°C, 3.2 at 41.8°C) and were similar to those for cisplatin killing (2.6 at 40.5°C, 3.6 at 41.8°C). In a separate experiment, cytotoxicity was additive when carboplatin and cisplatin were given simultaneously at 37°C and at 41.8°C. Etoposide, which synergizes with platinum agents, did not have supra-additive cytotoxic interactions with hyperthermia. The data presented are relevant to the conduct of clinical hyperthermia trials.